- Home
- CAI vs PCVX Comparison
CAI vs PCVX Comparison
Compare CAI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAI | PCVX |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 7.0B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAI | PCVX |
|---|---|---|
| Price | $26.55 | $62.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $30.91 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 5.0M | 908.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $812,033,000.00 | N/A |
| Revenue This Year | $25.24 | N/A |
| Revenue Next Year | $22.32 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 96.97 | N/A |
| 52 Week Low | $14.19 | $29.87 |
| 52 Week High | $40.40 | $65.00 |
Technical Indicators
Market Signals| Indicator | CAI | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 77.64 | 63.30 |
| Support Level | $25.11 | $52.18 |
| Resistance Level | $29.07 | $65.00 |
| Average True Range (ATR) | 1.23 | 2.20 |
| MACD | 0.54 | 0.50 |
| Stochastic Oscillator | 99.43 | 90.12 |
Price Performance
Historical ComparisonAbout CAI Caris Life Sciences Inc.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.